Targeting senescence as an anticancer therapy
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
Cellular senescence is a stress response elicited by different molecular insults. Senescence results in cell cycle exit and is characterised by multiple phenotypic changes such as the production of a bioactive secretome. Senescent cells accumulate during ageing and are present in cancerous and fibrotic lesions. Drugs that selectively kill senescent cells (senolytics) have shown great promise for the treatment of age‐related diseases. Senescence plays paradoxical roles in cancer. Induction of senescence limits cancer progression and contributes to therapy success, but lingering senescent cells fuel progression, recurrence, and metastasis. In this review, we describe the intricate relation between senescence and cancer. Moreover, we enumerate how current anticancer therapies induce senescence in tumour cells and how senolytic agents could be deployed to complement anticancer therapies. “One‐two punch” therapies aim to first induce senescence in the tumour followed by senolytic treatment to target newly exposed vulnerabilities in senescent tumour cells. “One‐two punch” represents an emerging and promising new strategy in cancer treatment. Future challenges of “one‐two punch” approaches include how to best monitor senescence in cancer patients to effectively survey their efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
Clearance of p16Ink4a-positive senescent cells delays ageing-associated disorders
Baker, D. J., Wijshake, T., Tchkonia, T., LeBrasseur, N. K., Childs, B. G., van de Sluis, B., Kirkland, J. L., & van Deursen, J. M. (2011) · Nature · doi:10.1038/nature10600 · Cited by 3,670
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
Self-citationA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917
Naturally occurring p16Ink4a-positive cells shorten healthy lifespan
Baker, D. J., Childs, B. G., Durik, M., Wijers, M. E., Sieben, C. J., Zhong, J., A. Saltness, R., Jeganathan, K. B., Verzosa, G. C., Pezeshki, A., et al. (2016) · Nature · doi:10.1038/nature16932 · Cited by 2,876
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
A landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584
Research works printed but not linked: 147
- 10.1016/j.tcb.2018.02.001 · DOI · Paper page
- 10.1091/mbc.e11-10-0884 · DOI · Paper page
- 10.1016/0014-4827(61)90192-6 · DOI · Paper page
- 10.1038/345458a0 · DOI · Paper page
- 10.1016/j.cell.2013.10.041 · DOI · Paper page
- 10.1016/j.cell.2008.06.049 · doi:10.1016/j.cell.2008.06.049 · Paper page
- 10.1038/s41568-022-00450-9 · DOI · Paper page
- 10.1158/0008-5472.CAN-20-0506 · DOI · Paper page
- 10.3389/fonc.2017.00278 · DOI · Paper page
- 10.1074/jbc.C300023200 · DOI · Paper page
- 10.1016/j.molcel.2021.10.017 · DOI · Paper page
- 10.1158/1078-0432.CCR-04-1462 · DOI · Paper page
- 10.1002/ijc.27810 · DOI · Paper page
- 10.1038/s41416-022-01787-6 · DOI
- 10.1038/nrc2603 · DOI · Paper page
- 10.1073/pnas.211053698 · DOI · Paper page
- 10.1158/0008-5472.CAN-08-2970 · DOI · Paper page
- 10.1016/j.arr.2016.05.011 · DOI
- 10.1016/j.canlet.2020.06.019 · DOI · Paper page
- Chang BD, 1999, A senescence‐like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents, Cancer Res, 59, 3761
- 10.1038/s41419-018-0303-9 · DOI · Paper page
- Wang X, 1998, Evidence of cisplatin‐induced senescent‐like growth arrest in nasopharyngeal carcinoma Cells1, Cancer Res, 58, 5019
- 10.1038/sj.bjc.6600711 · DOI · Paper page
- 10.1158/0008-5472.CAN-04-2633 · DOI · Paper page
- 10.1158/0008-5472.CAN-18-1733 · DOI · Paper page
- 10.1371/journal.pone.0055665 · DOI · Paper page
- 10.1038/sj.bjc.6604017 · DOI · Paper page
- Poele RH, 2002, DNA damage is able to induce senescence in tumor cells in vitro and in vivo, Cancer Res, 62, 1876
- 10.1074/jbc.M205477200 · DOI · Paper page
- 10.1074/jbc.M807930200 · DOI
- 10.1593/neo.05250 · DOI · Paper page
- 10.1042/bj20021950 · DOI · Paper page
- 10.1038/srep31758 · DOI · Paper page
- 10.1016/j.toxlet.2012.08.004 · DOI
- 10.18632/oncotarget.2774 · DOI · Paper page
- 10.18632/oncotarget.6126 · DOI · Paper page
- 10.1158/1078-0432.CCR-15-1421 · DOI · Paper page
- 10.3390/cells8121501 · DOI · Paper page
- 10.1158/1541-7786.MCR-08-0457 · DOI · Paper page
- 10.1016/j.bbrc.2016.06.063 · DOI
- 10.1016/j.bcp.2004.06.033 · DOI
- 10.18632/aging.102262 · DOI
- 10.1080/09553000500168549 · DOI · Paper page
- 10.3171/jns.2006.105.1.111 · DOI · Paper page
- 10.1038/ncomms15916 · DOI · Paper page
- 10.1016/j.yexcr.2017.09.031 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-4559 · DOI · Paper page
- 10.1158/1541-7786.MCR-20-0915 · DOI
- 10.1136/gutjnl-2016-312268 · DOI · Paper page
- 10.1038/s41388-018-0332-y · DOI · Paper page
- 10.4161/cc.26130 · DOI · Paper page
- 10.1016/j.ccell.2017.11.006 · DOI · Paper page
- 10.1016/j.ccell.2016.02.006 · DOI · Paper page
- 10.18632/oncotarget.17778 · DOI · Paper page
- 10.1158/1078-0432.CCR-18-0372 · DOI
- 10.18632/oncotarget.24585 · DOI · Paper page
- 10.1158/1535-7163.MCT-13-0137 · DOI · Paper page
- 10.1158/0008-5472.CAN-15-1336 · DOI · Paper page
- 10.1016/j.neo.2014.05.009 · DOI · Paper page
- 10.1016/j.lungcan.2010.10.016 · DOI
- 10.1093/gerona/62.3.246 · DOI
- 10.4149/neo_2011_01_35 · DOI · Paper page
- 10.1158/0008-5472.CAN-04-4608 · DOI · Paper page
- 10.1038/onc.2015.435 · DOI
- 10.1038/sj.onc.1209049 · DOI · Paper page
- 10.1016/j.canlet.2013.02.051 · DOI
- 10.1016/j.bbrc.2015.12.070 · DOI
- 10.1158/1541-7786.MCR-09-0300 · DOI · Paper page
- 10.1158/0008-5472.CAN-14-0386 · DOI
- 10.1016/j.pan.2022.03.019 · DOI
- 10.1074/jbc.M112.371682 · DOI
- 10.1155/2019/9014045 · DOI
- 10.1371/journal.pone.0111060 · DOI
- 10.18632/oncotarget.2844 · DOI
- 10.1002/1878-0261.12477 · DOI
- 10.1002/hep.32461 · DOI
- 10.1158/1557-3265.OVCA19-A29 · doi:10.1158/1557-3265.ovca19-a29
- 10.1002/pros.24342 · doi:10.1002/pros.24342
- 10.1038/nm.3993 · DOI · Paper page
- 10.3802/jgo.2019.30.e26 · DOI
- 10.1158/1535-7163.MCT-21-0604 · DOI
- Chatterjee P, 2013, PARP inhibition sensitizes to low dose‐rate radiation TMPRSS2‐ERG fusion gene‐expressing and PTEN‐deficient prostate cancer cells. PLOS ONE. Public library of, Science, 8, e60408
- 10.1158/0008-5472.CAN-09-4224 · DOI · Paper page
- 10.1016/j.lfs.2013.12.009 · DOI
- 10.1002/ijc.26239 · DOI
- 10.1371/journal.pone.0068003 · DOI
- 10.1002/pros.22571 · DOI · Paper page
- 10.1016/j.bcp.2021.114765 · DOI
- 10.1158/1535-7163.MCT-15-0627 · DOI
- 10.18632/oncotarget.25208 · DOI
- 10.1002/ijc.26179 · DOI · Paper page
- 10.1053/j.gastro.2015.03.016 · DOI
- 10.1016/j.radonc.2015.06.026 · DOI
- 10.1002/mc.22953 · DOI
- 10.1038/jid.2013.6 · DOI
- 10.1016/j.phrs.2022.106259 · DOI
- 10.1177/1087057109340314 · DOI · Paper page
- 10.1038/sj.onc.1203078 · DOI · Paper page
- 10.1016/j.canlet.2009.04.015 · DOI
- 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2 · DOI · Paper page
- 10.2174/13894501113149990198 · DOI · Paper page
- 10.1016/j.trsl.2019.03.006 · DOI · Paper page
- 10.1093/jnci/djt212 · DOI · Paper page
- 10.1038/s41419-021-03811-8 · DOI · Paper page
- 10.1158/1078-0432.CCR-19-1440 · DOI · Paper page
- 10.1200/jco.2014.32.15_suppl.2528 · DOI · Paper page
- Goel S, 2022, Targeting CDK4 and CDK6 in cancer, Nat Rev Cancer, 1
- 10.1016/j.ccell.2020.03.010 · DOI · Paper page
- 10.1158/0008-5472.CAN-15-0728 · DOI · Paper page
- 10.18632/oncotarget.2673 · DOI
- 10.1200/JCO.18.00925 · DOI · Paper page
- 10.3390/cancers12123566 · DOI · Paper page
- 10.1016/j.bbcan.2008.07.003 · DOI · Paper page
- 10.18632/oncotarget.14893 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-1405 · DOI · Paper page
- 10.3389/fonc.2015.00278 · DOI · Paper page
- 10.4161/cc.10.14.16494 · DOI · Paper page
- 10.1158/1535-7163.MCT-13-0012 · DOI
- 10.1016/j.biopha.2015.07.005 · DOI
- 10.1002/ijc.23607 · DOI · Paper page
- 10.1038/s41586-018-0387-5 · DOI · Paper page
- 10.1126/science.aam7344 · DOI · Paper page
- 10.1158/2159-8290.CD-13-0230 · DOI · Paper page
- 10.1038/ng.1026 · DOI · Paper page
- 10.1126/science.aaf6659 · DOI · Paper page
- 10.1038/s41418-020-0564-6 · DOI
- 10.1002/1878-0261.12761 · DOI · Paper page
- 10.1158/1541-7786.MCR-21-0029 · DOI
- 10.3390/cancers13143585 · DOI
- 10.3390/cancers13030386 · DOI · Paper page
- 10.1038/s41467-022-29824-1 · DOI · Paper page
- 10.1007/s00018-021-03980-x · DOI
- 10.1016/j.jconrel.2020.04.045 · DOI · Paper page
- 10.1016/j.ebiom.2021.103646 · DOI · Paper page
- 10.1038/nature03579 · DOI · Paper page
- 10.1038/nm.3048 · DOI · Paper page
- 10.3390/cells9071593 · DOI · Paper page
- 10.1002/anie.201204663 · DOI · Paper page
- 10.3390/jcm8040433 · DOI · Paper page
- 10.1056/NEJMoa1009290 · DOI · Paper page
- 10.1200/JCO.2012.48.3552 · DOI · Paper page
- 10.1158/1078-0432.CCR-10-0802 · DOI
- 10.1056/NEJMoa1510016 · DOI · Paper page
- 10.1056/NEJMoa1001671 · DOI · Paper page
- 10.1002/1878-0261.12807 · DOI · Paper page
- 10.1158/1538-7445.AM2018-LB-369 · DOI
- 10.1158/1538-7445.AM2019-1146 · DOI · Paper page
Cited by
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Zhou, Y., Tao, L., Qiu, J., Xu, J., Yang, X., Zhang, Y., Tian, X., Guan, X., Cen, X., & Zhao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01823-2 · Cited by 720
Senescence as a therapeutic target in cancer and age-related diseases
McHugh, D., Durán, I., & Gil, J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01074-4 · Cited by 197
Self-citationTargeting Cellular Senescence for Healthy Aging: Advances in Senolytics and Senomorphics
Alum, E., Izah, S., Uti, D., Ugwu, O., Betiang, P., Basajja, M., & Ejemot-Nwadiaro, R. (2025) · Drug Design, Development and Therapy · doi:10.2147/dddt.s543211 · Cited by 63
HDAC4 in cancer: A multitasking platform to drive not only epigenetic modifications
Cuttini, E., Goi, C., Pellarin, E., Vida, R., & Brancolini, C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1116660 · Cited by 28
Inhibition of glutaminase elicits senolysis in therapy-induced senescent melanoma cells
Kim, J., Brunetti, B., Kumar, A., Mangla, A., Honda, K., & Yoshida, A. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07284-3 · Cited by 16
Metadata
- Authors
- Bousset, L., & Gil, J.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2022-09-23
- Volume
- 16
- Issue
- 21
- Pages
- 3855-3880
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W4294794606
- Cited by
- 105
- References
- 119
- FWCI
- 10.14
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Cancer Research UK (C15075/A28647)
- Medical Research Council Canada (MC_U120085810)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting senescence as an anticancer therapy. https://app.cochat.ai/papers/10.1002/1878-0261.13312
- The paper
- Bousset, L., & Gil, J. (2022). Targeting senescence as an anticancer therapy. Molecular Oncology. https://doi.org/10.1002/1878-0261.13312
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.